- Poster presentation
- Open Access
Dispersion of hyperenhancement in late gadolinium enhancement cardiovascular magnetic resonance measured with Moran's I is associated with a decrement in LVEF 6 months after cardiotoxic chemotherapy
© Jordan et al; licensee BioMed Central Ltd. 2013
- Published: 30 January 2013
- Breast Cancer
- Left Ventricular Ejection Fraction
- Cardiovascular Magnetic Resonance
- Hematologic Malignancy
We performed a prospective, extramurally-funded longitudinal cohort study of 51 participants (43 women, 8 men; aged 52±2 years) scheduled to receive 3 to 4 months of potentially cardiotoxic chemotherapy (anthracycline or trastuzumab) for treatment of breast cancer or hematologic malignancy. Before and then 3 and 6 months after chemotherapy initiation, participants underwent cardiovascular magnetic resonance (CMR) assessments of LVEF, LGE-SI, and Moran's I statistic determined by personnel blinded to participant identifiers and all other aspects of the analyses. Results were analyzed using paired Student's t-tests to test for a difference between baseline and subsequent examinations, and one-way ANOVA to test for trending change. All values are reported as mean ± standard deviation with p-values<0.05 considered statistically signficant.
We observed that, six months after receipt of chemotherapy, increased late gadolinium enhancement signal intensity (LGE-SI) occurs in a diffusely distributed pattern within the myocardium concurrent with a declining LVEF. Moran's I statistic is a novel method to discriminate processes related to a diffuse increase in myocardial T1 (fibrosis, edema) from those related to a clustered increase in myocardial T1 (infarct); further investigations are warranted to study the utility of Moran's I statistic with T1 and T2 mapping.
This work was supported in part by the National Institutes of Health grant R33CA12196 (Hundley), American Heart Association Predoctoral Fellowship 09PRE2210050 (Jordan), and a grant from the Susan G. Komen Foundation BCTR07007769 (Hundley).
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.